These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25378228)

  • 41. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
    Conconi A; Martinelli G; Thiéblemont C; Ferreri AJ; Devizzi L; Peccatori F; Ponzoni M; Pedrinis E; Dell'Oro S; Pruneri G; Filipazzi V; Dietrich PY; Gianni AM; Coiffier B; Cavalli F; Zucca E
    Blood; 2003 Oct; 102(8):2741-5. PubMed ID: 12842999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The primary pulmonary Malt lymphoma: About a case].
    Moustarhfir Elidrissi A; Benjelloun H; Zaghba N; Yassine N
    Rev Pneumol Clin; 2017 Jun; 73(3):156-157. PubMed ID: 28365048
    [No Abstract]   [Full Text] [Related]  

  • 43. Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study.
    Min GJ; Rhee CK; Kim TY; Jeon YW; O JH; Choi BO; Park G; Cho SG
    Acta Haematol; 2024; 147(4):413-426. PubMed ID: 38008071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Neuper O; Mayerhoefer ME; Dolak W; Lukas J; Simonitsch-Klupp I; Raderer M
    Hematol Oncol; 2018 Feb; 36(1):49-55. PubMed ID: 28695630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma.
    Kahara T; Iwaki N; Kaya H; Kurokawa T; Yoshida T; Ishikura K; Usuda R
    Endocr J; 2011; 58(1):7-12. PubMed ID: 21068513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
    Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
    Kiesewetter B; Troch M; Mayerhoefer ME; Dolak W; Simonitsch-Klupp I; Raderer M
    Oncologist; 2016 Jan; 21(1):72-5. PubMed ID: 26621040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrence of IgG4-related disease following treatment with rituximab.
    Murakami J; Matsui S; Ishizawa S; Arita K; Wada A; Miyazono T; Hounoki H; Shinoda K; Taki H; Sugiyama T
    Mod Rheumatol; 2013 Nov; 23(6):1226-30. PubMed ID: 22956241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy.
    Bacalja J; Ulamec M; Rako D; Bošković L; Trnski D; Vrdoljak E; Krušlin B
    In Vivo; 2013; 27(4):545-9. PubMed ID: 23812229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. t(11;18)(q21;q21)-positive advanced-stage MALT lymphoma associated with monoclonal gammopathy: resistance to rituximab or rituximab-containing chemotherapy.
    Ohno H; Isoda K
    J Clin Exp Hematop; 2008 Nov; 48(2):47-54. PubMed ID: 19039196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma.
    Stalika E; Kanellis G; Papalexandri A; Iskas M; Vrakidou E; Demonakou M; Anagnostopoulos A; Stamatopoulos K; Papadaki T
    Leuk Lymphoma; 2014 Mar; 55(3):702-5. PubMed ID: 23725385
    [No Abstract]   [Full Text] [Related]  

  • 55. Rituximab-induced remission of a gastric MALT lymphoma.
    Datta YH; Kampalath B; Binion DG
    Leuk Lymphoma; 2004 Jun; 45(6):1297-9. PubMed ID: 15360017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Mucosa-associated lymphoid tissue lymphoma of the larynx].
    Hua J; Iwaki Y; Inoue M; Takiguchi Y; Ota Y; Hagihara M
    Rinsho Ketsueki; 2014 Mar; 55(3):340-4. PubMed ID: 24681938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
    Zinzani PL; Pellegrini C; Gandolfi L; Casadei B; Derenzini E; Broccoli A; Quirini F; Argnani L; Pileri S; Celli M; Fanti S; Poletti V; Stefoni V; Baccarani M
    Hematol Oncol; 2013 Dec; 31(4):183-8. PubMed ID: 23212941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
    Kang HJ; Kim WS; Kim SJ; Lee JJ; Yang DH; Kim JS; Lee SR; Lee GW; Kim HJ; Kim HY; Oh SY; Kim HC; Eom HS; Chung J; Park J; Suh C; Ryoo BY
    Ann Hematol; 2012 Apr; 91(4):543-51. PubMed ID: 21922208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.